Despite perceptions that biopesticides are inherently less dangerous, the EU regulates them as stringently as conventional, potentially highly hazardous, synthetic plant protection chemicals (Regulation [EC] No. 1107/2009). This has made approvals costly and slow. Recent regulatory revisions intended to redress this—to give EU farmers better and faster access to biological …
Biomarker Q&A: The landscape and outlook for precision medicine in neurology
Labcorp Drug Development has continued to invest in the technology, innovation and expertise globally to support clients focused on bringing life-changing treatments to patients with neurological diseases. We recently spoke with Robert Martone, Associate Director, Neurology Biomarkers with the Biomarker Solution Center, to learn about the acceleration and expansion of …
Biomarker Q&A: The power of precision medicine for kidney disease
Labcorp Drug Development has continued to invest in the technology, capacity and expertise globally to support the evolving and complex analytical needs of our clients. We recently spoke with Katherine T Landschulz, PhD, Sr. Director and Lead Scientist, Cardiovascular and Metabolic Disease, Neurodegeneration at Labcorp Drug Development, to learn about …
How patient-centricity embeds value and stability in LTFU studies
Phase I-III randomized controlled trials alone are not generating enough data to extrapolate conclusions and theories about therapeutics to the global population. Not all drugs demonstrate the same efficacy in the real world as shown in the clinical trials. Because of this, we are seeing a rise in long-term follow-up …
5 key takeaways from a Labcorp webinar: Current and emerging Parkinson’s disease biomarkers to advance clinical research
Insights from our three guest speakers: Robert Martone, Associate Director, Neurology Biomarkers, Labcorp Biomarker Solution Center, Labcorp Drug Development Hiba Kazmi, PhD, Biomarker Scientist, IXICO Antoniya Todorova, MD, PhD, Medical Director, Labcorp Drug Development On September 12, three leading biomarker specialists shared their insights on ongoing research in Parkinson’s disease …
Exploring metastatic breast cancer immunotherapies: Are ADCs and ICIs the answer?
Breast cancer is the most common malignancy in women and the second most common cancer worldwide.1 Rates of breast cancer are increasing in many parts of the world, reflecting its association with social and lifestyle factors related to economic development, as well as increases in life expectancy.2 Although the disease …
European Society for Medical Oncology: Understanding barriers to accessible cancer care
The European Society for Medical Oncology (ESMO) recently held its first in-person congress since the COVID-19 pandemic. The conference, held in Paris, brought together more than 22,000 attendees to share and discuss the latest evidence and issues in cancer care. A common thread running through the congress program was ESMO’s …
Cell and Gene Therapy Answers: The importance of designing trials and strategies with the end goals in mind
The cell and gene therapy landscape is experiencing a season of exponential growth within drug development. With more and more assets entering preclinical development every day, Darby Thomas, director in the Cell and Gene Therapy Alliance at Labcorp Drug Development, underscores the importance of designing trials and strategies with the …
5 tips for sponsors planning clinical trials in dialysis—Excerpts from a recent Labcorp webinar
Insight from our three guest speakers: Laura M. Dember, MD, Professor of Medicine and Epidemiology at the University of Pennsylvania Perelman School of Medicine Amy Young, VP and General Manager, DaVita Clinical Research Hans-Juergen Arens, PhD, VP, International Clinical Research Services, Global Medical Office, Frenova Renal Research Moderated by: Barbara …
snapClinical® team launches eSource module to revolutionize at-home care for Labcorp Drug Development Mobile Clinical Services
This is a special edition of the Labcorp Drug Development Decentralized Clinical Trial (DCT) blog. Labcorp Drug Development Mobile Clinical Services (MCS) team has now completed the first global visit utilizing the eSource module of the proprietary Labcorp DCT platform, snapClinical. This module represents a cross-functional effort to develop a …